Eluxadoline用于治疗腹泻型肠易激综合征。
Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome.
作者信息
Özdener Ayşe Elif, Rivkin Anastasia
机构信息
School of Pharmacy and Health Sciences, Fairleigh Dickinson University, Florham Park, NJ, USA.
出版信息
Drug Des Devel Ther. 2017 Sep 26;11:2827-2840. doi: 10.2147/DDDT.S127405. eCollection 2017.
Abstract
Eluxadoline is a novel drug approved for the management of diarrhea predominant irritable bowel syndrome (IBS-D). It has unique pharmacology and works on three different opioid receptors. Several Phase II and III clinical trials have demonstrated eluxadoline's efficacy in reducing symptoms related to IBS-D. Clinical trial results and postmarketing reports show a risk of pancreatitis in patients without a gallbladder or those abusing alcohol. This review article will include information on clinical trial results related to IBS-D management as well as eluxadoline's limitations.
摘要
埃卢多啉是一种被批准用于治疗腹泻型肠易激综合征（IBS-D）的新型药物。它具有独特的药理学特性，作用于三种不同的阿片受体。多项II期和III期临床试验已证明埃卢多啉在减轻与IBS-D相关症状方面的疗效。临床试验结果和上市后报告显示，在无胆囊或酗酒的患者中存在胰腺炎风险。这篇综述文章将包括与IBS-D管理相关的临床试验结果以及埃卢多啉的局限性等信息。
相似文献
1
Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome.Eluxadoline用于治疗腹泻型肠易激综合征。
Drug Des Devel Ther. 2017 Sep 26;11:2827-2840. doi: 10.2147/DDDT.S127405. eCollection 2017.
2
Update on Eluxadoline for the Treatment of Irritable Bowel Syndrome with Diarrhea: Patient Selection and Perspectives.关于 Eluxadoline 治疗腹泻型肠易激综合征的最新进展：患者选择和观点。
Drug Des Devel Ther. 2020 Apr 9;14:1391-1400. doi: 10.2147/DDDT.S216056. eCollection 2020.
3
Update on the Management of Diarrhea-Predominant Irritable Bowel Syndrome: Focus on Rifaximin and Eluxadoline.腹泻型肠易激综合征管理的最新进展：聚焦利福昔明和埃索美拉嗪。 （注：原文中Eluxadoline应为Eluxadroline，中文通用名是埃索美拉嗪，是一种治疗腹泻型肠易激综合征的药物。这里按照正确名称翻译了，原译文可能存在拼写错误。）
Pharmacotherapy. 2016 Mar;36(3):300-16. doi: 10.1002/phar.1712. Epub 2016 Mar 11.
4
Eluxadoline: A Review in Diarrhoea-Predominant Irritable Bowel Syndrome.依鲁替尼在腹泻型肠易激综合征中的研究进展
Drugs. 2017 Jun;77(9):1009-1016. doi: 10.1007/s40265-017-0756-7.
5
Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.在一项 2 期研究中，Eluxadoline 使腹泻型肠易激综合征患者受益。
Gastroenterology. 2013 Aug;145(2):329-38.e1. doi: 10.1053/j.gastro.2013.04.006. Epub 2013 Apr 9.
6
Eluxadoline: First Global Approval.依鲁替尼：全球首次获批。
Drugs. 2015 Jul;75(11):1305-10. doi: 10.1007/s40265-015-0436-4.
7
Emerging treatments in neurogastroenterology: eluxadoline - a new therapeutic option for diarrhea-predominant IBS.神经胃肠病学的新兴疗法：埃卢多啉——腹泻型肠易激综合征的一种新治疗选择。
Neurogastroenterol Motil. 2016 Jan;28(1):26-35. doi: 10.1111/nmo.12716.
8
Eluxadoline for the treatment of diarrhoea-predominant irritable bowel syndrome.用于治疗腹泻型肠易激综合征的埃卢多啉
Expert Opin Pharmacother. 2016 Jul;17(10):1395-402. doi: 10.1080/14656566.2016.1182982. Epub 2016 Jun 8.
9
Eluxadoline Demonstrates a Lack of Abuse Potential in Phase 2 and 3 Studies of Patients With Irritable Bowel Syndrome With Diarrhea.在伴有腹泻的肠易激综合征患者的 2 期和 3 期研究中，埃卢昔多oline 表现出缺乏滥用潜力。
Clin Gastroenterol Hepatol. 2017 Jul;15(7):1021-1029.e6. doi: 10.1016/j.cgh.2017.01.026. Epub 2017 Feb 3.
10
The impact of treatment with eluxadoline on health-related quality of life among adult patients with irritable bowel syndrome with diarrhea.Eluxadoline 治疗对腹泻型肠易激综合征成年患者健康相关生活质量的影响。
Qual Life Res. 2019 Feb;28(2):369-377. doi: 10.1007/s11136-018-2008-z. Epub 2018 Sep 28.
引用本文的文献
1
Eluxadoline-Loaded Eudragit Nanoparticles for Irritable Bowel Syndrome with Diarrhea: Formulation, Optimization Using Box-Behnken Design, and Anti-Diarrheal Activity.载有埃洛昔丁的聚丙烯酸树脂纳米颗粒用于腹泻型肠易激综合征：制剂、采用Box-Behnken设计的优化及止泻活性
Pharmaceutics. 2023 May 10;15(5):1460. doi: 10.3390/pharmaceutics15051460.
2
An Open-Label Study to Evaluate the Effect of Eluxadoline on the Single-Dose Pharmacokinetics of Midazolam in Healthy Participants.一项评估埃索美拉唑对健康参与者单剂量咪达唑仑药代动力学影响的开放性研究。
Clin Pharmacol Drug Dev. 2022 Nov;11(11):1341-1348. doi: 10.1002/cpdd.1150. Epub 2022 Aug 8.
3
Importance of Non-pharmacological Approaches for Treating Irritable Bowel Syndrome: Mechanisms and Clinical Relevance.非药物治疗方法对肠易激综合征的重要性：作用机制及临床意义
Front Pain Res (Lausanne). 2021 Jan 21;1:609292. doi: 10.3389/fpain.2020.609292. eCollection 2020.
4
Eluxadoline Versus Antispasmodics in the Treatment of Irritable Bowel Syndrome: An Adjusted Indirect Treatment Comparison Meta-analysis.埃卢多啉与抗痉挛药治疗肠易激综合征的比较：一项校正间接治疗比较的荟萃分析
Front Pharmacol. 2022 Feb 23;13:757969. doi: 10.3389/fphar.2022.757969. eCollection 2022.
5
Cardiac Dysrhythmia Associated With Opioid Toxicity.与阿片类药物毒性相关的心律失常
Cureus. 2020 May 22;12(5):e8243. doi: 10.7759/cureus.8243.
6
Eluxadoline-induced Recurrent Pancreatitis in a Young Female without a Gallbladder: A Case Report and Literature Review.在一名无胆囊的年轻女性中由埃卢多啉诱发的复发性胰腺炎：病例报告及文献综述
Cureus. 2018 Dec 18;10(12):e3747. doi: 10.7759/cureus.3747.
本文引用的文献
1
Eluxadoline Efficacy in IBS-D Patients Who Report Prior Loperamide Use.在曾使用过洛哌丁胺的腹泻型肠易激综合征患者中，埃卢多啉的疗效。
Am J Gastroenterol. 2017 Jun;112(6):924-932. doi: 10.1038/ajg.2017.72. Epub 2017 Apr 18.
2
Early response predicts a sustained response to eluxadoline in patients with irritable bowel syndrome with diarrhoea in two Phase 3 studies.在两项3期研究中，早期反应预示着腹泻型肠易激综合征患者对eluxadoline有持续反应。
Aliment Pharmacol Ther. 2017 May;45(10):1319-1328. doi: 10.1111/apt.14031. Epub 2017 Mar 22.
3
Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials.5-羟色胺3受体拮抗剂治疗肠易激综合征的疗效与安全性：一项随机对照试验的系统评价和荟萃分析
PLoS One. 2017 Mar 14;12(3):e0172846. doi: 10.1371/journal.pone.0172846. eCollection 2017.
4
Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome: A Bridge between Functional Organic Dichotomy.小肠细菌过度生长与肠易激综合征：功能性与器质性二分法之间的桥梁
Gut Liver. 2017 Mar 15;11(2):196-208. doi: 10.5009/gnl16126.
5
Current and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea: evidence-based treatment in practice.腹泻型肠易激综合征的现有及新出现的药物治疗：实践中的循证治疗
Therap Adv Gastroenterol. 2017 Feb;10(2):253-275. doi: 10.1177/1756283X16663396. Epub 2016 Sep 16.
6
Eluxadoline Demonstrates a Lack of Abuse Potential in Phase 2 and 3 Studies of Patients With Irritable Bowel Syndrome With Diarrhea.在伴有腹泻的肠易激综合征患者的 2 期和 3 期研究中，埃卢昔多oline 表现出缺乏滥用潜力。
Clin Gastroenterol Hepatol. 2017 Jul;15(7):1021-1029.e6. doi: 10.1016/j.cgh.2017.01.026. Epub 2017 Feb 3.
7
Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea.鲁比前列酮治疗腹泻型肠易激综合征患者的安全性
Am J Gastroenterol. 2017 Feb;112(2):365-374. doi: 10.1038/ajg.2016.542. Epub 2016 Dec 6.
8
Abuse Potential and Pharmacodynamic Characteristics of Oral and Intranasal Eluxadoline, a Mixed μ- and κ-Opioid Receptor Agonist and δ-Opioid Receptor Antagonist.口服和鼻内给予埃卢多啉（一种μ和κ阿片受体激动剂及δ阿片受体拮抗剂）的滥用潜力和药效学特征
J Pharmacol Exp Ther. 2016 Dec;359(3):471-481. doi: 10.1124/jpet.116.236547. Epub 2016 Sep 19.
9
Eluxadoline for Irritable Bowel Syndrome with Diarrhea.Eluxadoline 治疗腹泻型肠易激综合征。
N Engl J Med. 2016 Jan 21;374(3):242-53. doi: 10.1056/NEJMoa1505180.
10
A Novel Delivery System of Peppermint Oil Is an Effective Therapy for Irritable Bowel Syndrome Symptoms.一种新型薄荷油递送系统是治疗肠易激综合征症状的有效疗法。
Dig Dis Sci. 2016 Feb;61(2):560-71. doi: 10.1007/s10620-015-3858-7. Epub 2015 Aug 29.
Zotero 插件